Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics

Catalyst Pharmaceuticals (NASDAQ: CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a recent discussion with Barclays life sciences analyst Glen Santangelo. Chief Executive Officer Rich Daly also reviewed early commercial progress for Agamree in Duchenne muscular dystrophy (DMD), provided an update